Recipient organisationNIHR Biomedical Research Centre at the Royal Marsden and the ICRSource-published name: NIHR Royal Marsden Biomedical Research Centre
NIHR supportRecorded as supported by this research centre
PeriodFeb 2025 — Apr 2027
In plain English
AI plain-English summary
A new drug called ABBV-525 is being tested for the first time in humans to see if it can safely treat several types of blood cancer that have stopped responding to standard therapies. Around 150 patients worldwide with relapsed or refractory B-cell non-Hodgkin lymphoma—including forms like diffuse large B-cell lymphoma and follicular lymphoma—will receive the drug daily by mouth. The study will last about 64 months. ABBV-525 works by blocking a protein called MALT1, which normally helps B cells grow but also keeps cancer cells alive. Laboratory studies in animals suggest the drug may kill or stop these malignant cells. If the drug proves safe and effective, it could offer a new treatment option for patients whose cancers have resisted existing therapies. This is early-stage, first-in-human research focused on safety and dosing, not yet a test of widespread clinical benefit. However, similar fundamental studies of targeted inhibitors have previously led to transformative treatments for blood cancers, changing how oncologists manage these diseases.
View original technical description
This is a first in human multicenter study being conducted by AbbVie Deutschland GmbH & Co. KG for those participants with relapsed/refractory (R/R) B-cell non-Hodgkin’s Lymphoma (NHL) (chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), or Waldenstrom’s Macroglobulinemia (WM)) Non-Hodgkin’s Lymphoma is a type of blood cancers also known as hematological cancers. Lymphoma develops when white blood cells called lymphocytes grow out of control. Lymphocytes are part of the immune system, which helps to fight infection. There are different types of non-Hodgkin lymphoma depending on how the cells are affected and the cancer behaves. The purpose of this study is to see if ABBV-525 the study drug, is safe and tolerable in participants with R/R NHL. The study aims to find out a safe and tolerable dose and schedule of ABBV-525, understand how much ABBV-525 is in the blood at specific times after dosing, to see whether ABBV-525 is effective in treating B-cell malignancies and to understand whether there are any changes to the way the participant’s heart beats when ABBV-525 is taken.The study drug has been studied in laboratory animals, but it has not been studied in humans. ABBV-525 is a MALT1 inhibitor (MALT1i) being developed as a treatment for B-cell NHL. The MALT1 protein helps normal B cells grow. It has also been shown to help cancer cells live and grow. By inhibiting or “blocking” MALT1, ABBV-525 may kill the cancer cells or stop them from growing.All participants will receive ABBV-525 orally once daily. The study will last about 64 months. The amount of time enrolled participants will be on study treatment or be followed up for health information as part of the study depends on how enrolled participants respond to and tolerate the study treatment.Approximately 150 participants will take part in this world-wide study.
Plain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research.
Is something wrong? Let us know